{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:42:09Z","timestamp":1787614929316,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"25","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,20]]},"abstract":"<jats:p>\n                    Antithrombotic therapy following left atrial appendage occlusion (LAAO) is recommended to prevent device-induced thrombosis and stroke. Guidelines suggest oral anticoagulants and aspirin for the first 45 days and then dual antiplatelet therapy for 6 months. However, regimens for antithrombotic therapy varies widely. This study aimed to assess the characteristics of patients receiving minimal versus standard antithrombotic therapy post-LAAO, and to examine the association between treatment type and thrombotic\/bleeding risk scores. We conducted a retrospective observational study of patients who underwent LAAO at a teaching hospital between April and December 2023. Patients were categorized into minimal (DOAC only) or standard (DOAC plus aspirin) therapy groups during the first 45 days, and into minimal (SAPT) or standard (DAPT) groups from 45 days to 6 months. Outcomes included CHA2DS2-VASc and HAS-BLED scores, comorbidities, and bleeding\/thrombotic events. Statistical analyses included univariate and bivariate comparisons using Chi-square, Fisher exact test, and\n                    <jats:italic toggle=\"yes\">t<\/jats:italic>\n                    -tests. Among 33 patients, 82% received minimal therapy and 18% for the standard therapy in the first 45 days. Standard therapy patients had higher rates of transient ischemic attack (50% vs 7.5%), stroke (100% vs 37%), coronary artery disease (100% vs 44.4%), and NSAID use (33.3% vs 3.7%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.05). The CHA2DS2-VASc scores were significantly higher in the standard group (6.5\u2005\u00b1\u20050.5 vs 4.6\u2005\u00b1\u20051.4,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002), with no difference in HAS-BLED scores. From 45 days to 6 months, 15.2% received minimal and 84.8% for the standard therapy, with no significant differences in scores. Patients with lower CHA2DS2-VASc scores were more likely to receive minimal therapy, indicating potential for risk-guided antithrombotic management post-LAAO. Further studies are needed to validate individualized treatment strategies.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000042885","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T17:01:01Z","timestamp":1750698061000},"page":"e42885","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Left atrial appendage occlusion procedure and antithrombotics: less may be enough for lower risk patients: A single-center observational study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3694-4335","authenticated-orcid":false,"given":"Myung-Rho","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2115-2683","authenticated-orcid":false,"given":"Jasmine","family":"Dugal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4410-2932","authenticated-orcid":false,"given":"Shawn","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Kirk Kerkorian School of Medicine at UNLV, University of Nevada, Las Vegas, NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4935-943X","authenticated-orcid":false,"given":"Spencer","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Medical Education, Kirk Kerkorian School of Medicine at UNLV, University of Nevada, Las Vegas, NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhani","family":"Goel","sequence":"additional","affiliation":[{"name":"Undergraduate Public Health Program, School of Public Health, University of Nevada, Las Vegas, NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaan","family":"Shafi","sequence":"additional","affiliation":[{"name":"Division of Cardiac Electrophysiology, Department of Internal Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7247-2213","authenticated-orcid":false,"given":"Aditi","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Batra","sequence":"additional","affiliation":[{"name":"Office of Research and Department of Medical Education, Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260613","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"R2-20260613","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1001\/jama.2014.15192","article-title":"Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.","volume":"312","author":"Reddy","year":"2014","journal-title":"JAMA"},{"key":"R3-20260613","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy.","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R4-20260613","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"R5-20260613","first-page":"2719","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation developed with the special contribution of the European Heart Rhythm Association.","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"R6-20260613","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/CIRCULATIONAHA.118.035090","article-title":"Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes.","volume":"138","author":"Dukkipati","year":"2018","journal-title":"Circulation"},{"key":"R7-20260613","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/eurheartj\/ehaa169","article-title":"Left atrial appendage occlusion with the AmplatzerTM AmuletTM device: full results of the prospective global observational study.","volume":"41","author":"Hildick-Smith","year":"2020","journal-title":"Eur Heart J"},{"key":"R8-20260613","doi-asserted-by":"crossref","first-page":"e1038","DOI":"10.4244\/EIJ-D-22-00627","article-title":"Left atrial appendage occlusion.","volume":"18","author":"Holmes","year":"2023","journal-title":"EuroIntervention"},{"key":"R10-20260613","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/jcm13030803","article-title":"Left atrial appendage occlusion and post-procedural antithrombotic management.","volume":"13","author":"Kramer","year":"2024","journal-title":"J Clin Med"},{"key":"R11-20260613","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/j.jacc.2013.03.035","article-title":"Left atrial appendage closure with the watchman device in patients with a contraindication for oral anticoagulation.","volume":"61","author":"Reddy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R12-20260613","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left atrial appendage closure versus direct oral anticoagulants in high-risk patients with atrial fibrillation.","volume":"75","author":"Osmancik","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R13-20260613","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.jcin.2021.07.031","article-title":"Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion.","volume":"14","author":"Della Rocca","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"R14-20260613","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.120.050117","article-title":"Primary outcome evaluation of a next-generation left atrial appendage closure device.","volume":"143","author":"Kar","year":"2021","journal-title":"Circulation"},{"key":"R15-20260613","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/europace\/euac270","article-title":"Real-world clinical outcomes with a next-generation left atrial appendage closure device: the FLXibility Post-Approval Study.","volume":"25","author":"Betts","year":"2023","journal-title":"Europace"},{"key":"R16-20260613","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"R17-20260613","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey.","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"R19-20260613","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCEP.118.006841","article-title":"Evaluating real-world clinical outcomes in atrial fibrillation patients receiving the WATCHMAN left atrial appendage closure technology.","volume":"12","author":"Boersma","year":"2019","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R21-20260613","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/CIRCULATIONAHA.121.057063","article-title":"Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial.","volume":"144","author":"Lakkireddy","year":"2021","journal-title":"Circulation"},{"key":"R22-20260613","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.121.057859","article-title":"Amulet or watchman device for percutaneous left atrial appendage closure: primary results of the SWISS-APERO randomized clinical trial.","volume":"145","author":"Galea","year":"2022","journal-title":"Circulation"},{"key":"R24-20260613","doi-asserted-by":"crossref","first-page":"ytae135","DOI":"10.1093\/ehjcr\/ytae135","article-title":"First-in-human left atrial appendage closure using the WATCHMAN FLX Pro device: a case report.","volume":"8","author":"Nielsen-Kudsk","year":"2024","journal-title":"Eur Heart J Case Rep"},{"key":"R25-20260613","doi-asserted-by":"crossref","first-page":"e4556400","DOI":"10.1155\/2021\/4556400","article-title":"Preclinical assessment of a novel conformable foam-based left atrial appendage closure device.","volume":"2021","author":"Sommer","year":"2021","journal-title":"Biomed Res Int"},{"key":"R26-20260613","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1016\/j.jcin.2021.08.060","article-title":"Conformal left atrial appendage seal device for left atrial appendage closure.","volume":"14","author":"Sommer","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"R27-20260613","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jcin.2023.04.028","article-title":"Transcatheter left atrial appendage exclusion: preclinical and early clinical results with the laminar device.","volume":"16","author":"Wong","year":"2023","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T13:01:36Z","timestamp":1781355696000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":23,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042885","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}